Up to 20 cancer centers will be invited to take part in the trials, which will be led by Dr Daniel Haller, of the University of Pennsylvania, Philadelphia, USA.
Avicine blocks human chorionic gonadotropin
Patients will be randomized to receive the Avicine vaccine in combination with chemotherapy or chemotherapy on its own.
Avicine blocks the ability of human chorionic gonadotropin to facilitate tumor growth.
Results of phase II trials involving more than 200 patients were reported last May to the American Society of Clinical Oncology and showed 'significant survival benefits', according to developers AVI Biopharma, of Portland, Oregon, USA. A phase II trial of its use for pancreatic cancer is now under way.
Dr Denis Burger, chief executive officer of AVI, said, "This represents the final stage in the development of Avicine and is a landmark for AVI. We are very pleased that the data from our previous five trials have set a solid foundation for this pivotal study."
Report Copyright: Englemed Health News at http://www.internationalmedicalnews.com